These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10868306)

  • 1. Update to the PhRMA perspective on population and individual bioequivalence.
    Barrett JS; Batra V; Chow A; Cook J; Gould AL; Heller AH; Lo MW; Patterson SD; Smith BP; Stritar JA; Vega JM; Zariffa N
    J Clin Pharmacol; 2000 Jun; 40(6):571-2. PubMed ID: 10868306
    [No Abstract]   [Full Text] [Related]  

  • 2. PhRMA perspective on population and individual bioequivalence.
    Barrett JS; Batra V; Chow A; Cook J; Gould AL; Heller AH; Lo MW; Patterson SD; Smith BP; Stritar JA; Vega JM; Zariffa N
    J Clin Pharmacol; 2000 Jun; 40(6):561-70. PubMed ID: 10868305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individual bioequivalence: attractive in principle, difficult in practice.
    Endrenyi L; Amidon GL; Midha KK; Skelly JP
    Pharm Res; 1998 Sep; 15(9):1321-5. PubMed ID: 9755880
    [No Abstract]   [Full Text] [Related]  

  • 4. The U.S. draft guidance regarding population and individual bioequivalence approaches: comments by a research-based pharmaceutical company.
    Hauschke D; Steinijans VW
    Stat Med; 2000 Oct; 19(20):2769-74. PubMed ID: 11033574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individual bioequivalence revisited.
    Chen ML; Lesko LJ
    Clin Pharmacokinet; 2001; 40(10):701-6. PubMed ID: 11707058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability and bioequivalence requirements: abbreviated applications. Final Rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Dec; 67(244):77668-75. PubMed ID: 12492102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subject-by-formulation interaction in bioequivalence: conceptual and statistical issues. FDA Population/Individual Bioequivalence Working Group. Food and Drug Administration.
    Hauck WW; Hyslop T; Chen ML; Patnaik R; Williams RL
    Pharm Res; 2000 Apr; 17(4):375-80. PubMed ID: 10870978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individual bioequivalence--a regulatory update.
    Chen ML
    J Biopharm Stat; 1997 Mar; 7(1):5-11. PubMed ID: 9056581
    [No Abstract]   [Full Text] [Related]  

  • 9. Mean difference vs. variability reduction: tradeoffs in aggregate measures for individual bioequivalence. FDA Individual Bioequivalence Working Group.
    Hauck WW; Chen ML; Hyslop T; Patnaik R; Schuirmann D; Williams R
    Int J Clin Pharmacol Ther; 1996 Dec; 34(12):535-41. PubMed ID: 8996848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The bioequivalence of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The bootstrap in bioequivalence studies.
    Pigeot I; Hauschke D; Shao J
    J Biopharm Stat; 2011 Nov; 21(6):1126-39. PubMed ID: 22023681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug bioequivalence. Recommendations from the Drug Bioequivalence Study Panel to the Office of Technology Assessment, Congress of the United States.
    J Pharmacokinet Biopharm; 1974 Oct; 2(5):433-66. PubMed ID: 4452945
    [No Abstract]   [Full Text] [Related]  

  • 13. The basis for individual bioequivalence. FDA Population and Individual Bioequivalence Working Group.
    Williams RL; Patnaik RN; Chen ML
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):13-7. PubMed ID: 11032083
    [No Abstract]   [Full Text] [Related]  

  • 14. Commentary on the FDA draft guidance for bioequivalence studies for nasal aerosols and nasal sprays for local action: an industry view.
    Harrison LI
    J Clin Pharmacol; 2000 Jul; 40(7):701-7. PubMed ID: 10883410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A modified large sample approach in the assessment of population bioequivalence.
    Quiroz J; Ting N; Wei GC; Burdick RK
    J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Requirements for submission of bioequivalence data; final rule. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jan; 74(11):2849-62. PubMed ID: 19385107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioequivalence: the regulatory career of a pharmaceutical concept.
    Carpenter D; Tobbell DA
    Bull Hist Med; 2011; 85(1):93-131. PubMed ID: 21551918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generic bioequivalence: a scientific consensus needed.
    Am Fam Physician; 1987 Feb; 35(2):91, 95. PubMed ID: 3812175
    [No Abstract]   [Full Text] [Related]  

  • 19. Sample size considerations for establishing clinical bioequivalence of allergen formulations.
    Rabin RL; Slater JE; Lachenbruch P; Pastor RW
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2003; (94):24-33. PubMed ID: 15119019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.